Fulcrum Therapeutics, Inc. (FULC) Profit Margins
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
FULCFulcrum Therapeutics, Inc.Follow FULC — free
—
Price chart with a free account
- Market cap
- 280.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 93.3% | — | 97.4% | — | — | |
| Operating margin | -811.6% | -423.0% | -1774.9% | -3945.2% | -27.4% | — | — | |
| Net margin | -802.7% | -421.9% | -1732.4% | -3470.1% | -12.2% | — | — | |
| FCF margin | -623.3% | -418.5% | -1561.2% | -3261.1% | -3.1% | — | — |
USD millions · SEC XBRL
Every figure on this page comes from Fulcrum Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.